483
Estee Lauder N.V.FDA 483 - Estee Lauder N.V. - April 26, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Estee Lauder N.V., an OTC drug manufacturer in Oevel, Belgium, from April 22-26, 2024, identified a significant deficiency in their quality control. The firm's quality unit failed to adequately test incoming high-risk drug components for impurities. This lapse raises concerns about the purity and safety of OTC drug products manufactured and distributed to the U.S. market.
Open in Dashboard
ID · 531b8974-ef1d-4fac-96a8-c0edfb27f68b